1. Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump (s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994; 38:1742-1752.
2. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad – spectrum β- lactamases conferring transferable resistance to newer β- lactam agents in Enterobacteriaceae hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
3. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003; 47:2385-2392.
4. Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother 1994; 38: 104-114.
5. Vahaboglu H, Oztürk R, Aygün G, Coşkunkan F, Yaman A, Kaygusuz A, et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41:2265-2269.
6. MacFaddin JF.Biochemical tests for identification of medical bacteria. 3rded. New York : Liooincott Williams AND Wilkins; 2000.p.689-690,705-771.
7. Clinical and Laboratory Standards Institute performance standards for antimicrobial susceptibility testing: Document M10 – S15.CLSI. Wayne, PA, USA, 2005.
8. Naas T, Nordmann P, Heidt A. Intercountry transfer of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter baumannii from Romania. Int J Antimicrob Agents 2007; 29: 226–228.
9. Akhi MT, Farzaneh F, Oskouei M. Study of enterococcal susceptibility patterns isolated from clinical specimens in Tabriz, Iran. Pak J Med Sci 2009; 25:211- 216.
10. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients. Burns 2009; 36:70- 74.
11. Lee S, Park YJ, Kim M, Lee HK, Han K, Kang CS, et al. Prevalence of Ambler class A and D beta-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 2005; 56:122-127.
12. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11:17-32.
13. Celenza G, Pellegrini C, Caccamo M, Segatore B, Amicosante G, Perilli M. Spread of bla (CTX-M-type) and bla (PER-2) beta-lactamase genes in clinical isolates from Bolivian Hospitals. J Antimicrob Chemother 2006; 57:975-978.
14. Chayakulkeeree M, Junsriwong P, Keerasuntonpong A, Tribuddharat C, Thamlikitkul V. Epidemiology of extended-spectrum beta-lactamase producing gram-negative bacilli at Siriraj Hospital, Thailand, 2003. Southeast Asian J Trop Med Public Health 2005; 36:1503-1509.
15. Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H; Study Group. PER-1 is still widespread in Turkish Hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett 2005; 249:241-245.